Navigation Links
Lymphoma Research Foundation and John Theurer Cancer Center collaborate for Lymphoma Rounds program
Date:6/14/2011

PHILADELPHIA, PA (June 14, 2011) On June 15, the Lymphoma Research Foundation (LRF), in collaboration with the John Theurer Cancer Center at Hackensack University Medical Center, will bring together lymphoma experts to discuss the latest practices in the diagnosis and management of lymphoma. This event is the final installation of LRF's 2010-2011 Philadelphia Lymphoma Rounds program, a continuing medical education (CME) series focused on the diagnosis and treatment of lymphoma patients.

"The Philadelphia Lymphoma Round Program is an opportunity for clinicians to better understand the latest lymphoma treatment advancements and apply these findings to their practice," said Anthony Mato, M.D., Program Chair and Lymphoma Attending at the John Theurer Cancer Center. "The treatment of lymphoma is rapidly changing, and we are committed to forums like this to keep the latest information accessible to physicians across the country."

The Lymphoma Rounds program provides a forum for local healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Participants network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by local lymphoma experts. The Philadelphia Lymphoma Rounds program is chaired by Stephen Schuster, M.D., Associate Professor of Medicine at the University of Pennsylvania.

"Lymphoma Rounds are an integral part of the Lymphoma Research Foundation's professional education services," said Brian Tomlinson, LRF's Chief Program Officer. "We are thrilled to work with the John Theurer Cancer Center for the final Philadelphia Lymphoma Rounds program of the 2010-2011 year, and to enable attendees to benefit from the collaboration of lymphoma experts from the leading Philadelphia-area institutions."

This program is free for healthcare professionals; however, pre-registration is required and available online. The University of Nebraska Medical Center, Center for Continuing Education designates this educational activity for a maximum of 1.5 AMA PRA Category I Credit.

Food and refreshments will be provided for all registered participants. The event will be held at the Philadelphia Westin Hotel, 99 South 17th Street, Philadelphia, PA. For additional information, please contact Max Mulcahy at the Lymphoma Research Foundation at mmulcahy@lymphoma.org or register for the event at www.lymphoma.org/PLR.

The Lymphoma Research Foundation is presenting this meeting in collaboration with the John Theurer Cancer Center, Cooper University Hospital, Fox Chase Cancer Center, Helen F. Graham Cancer Center, Thomas Jefferson University, and University of Pennsylvania, and Vita Medical Associates. The complete 2011-2012 Lymphoma Rounds program schedule will be available in the Fall.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. Vaccine increases disease-free survival for follicular lymphoma patients
2. Could Dogs DNA Give Clues to Human Lymphoma?
3. Sniffing out lymphoma by turning dogs into humans
4. 2 proteins play key roles in Burkitts lymphoma
5. Gene Mutation Suggests New Treatment Target for Specific Lymphoma
6. Study Adds to Evidence That Rituximab Slows Lymphoma Symptoms
7. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
8. New standards of care and novel treatment options for several forms of lymphoma unveiled
9. Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade
10. New lymphoma therapy may be more effective with fewer side effects
11. New mutation linked to non-Hodgkins lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: